IsoPlexis Corp. has entered a collaboration with Nektar Therapeutics focused on further defining the functional impact of NKTR-214 in the clinic, at the single-cell level, with the goal of revealing both mechanism and potential immune correlates with outcome.  Recent preclinical data captured by IsoPlexis’ IsoCode Chip showed evidence that Nektar’s cytokine agonist NKTR-214 can significantly boost the activation of critical T cell subsets, termed polyfunctional T cells, in combina...